| Pharmaceutical Information |
| Drug Name |
Reboxetine |
| Drug ID |
BADD_D01919 |
| Description |
Reboxetine is an antidepressant drug used in the treatment of clinical depression, panic disorder and ADD/ADHD. Its mesylate (i.e. methanesulfonate) salt is sold under tradenames including Edronax, Norebox, Prolift, Solvex, Davedax or Vestra. Reboxetine has two chiral centers, but it only exists as two enantiomers, (R,R)-(-)- and (S,S)-(+)-reboxetine. |
| Indications and Usage |
For the treatment of clinical depression. |
| Marketing Status |
approved; experimental |
| ATC Code |
N06AX18 |
| DrugBank ID |
DB00234
|
| KEGG ID |
D08472
|
| MeSH ID |
D000077593
|
| PubChem ID |
127151
|
| TTD Drug ID |
D0N8FQ
|
| NDC Product Code |
Not Available |
| UNII |
947S0YZ36I
|
| Synonyms |
Reboxetine | Reboxetine Mesylate | 2-((2-Ethoxyphenoxy)benzyl)morpholine methanesulfonate | Vestra |
|
| Chemical Information |
| Molecular Formula |
C19H23NO3 |
| CAS Registry Number |
71620-89-8 |
| SMILES |
CCOC1=CC=CC=C1OC(C2CNCCO2)C3=CC=CC=C3 |
| Chemical Structure |
|
|
| ADRs Induced by Drug |
|
|
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
|
|
|
